Here’s why the Race Oncology (ASX:RAC) share price is climbing today

Why is Race Oncology making the heart tick today?

| More on:
A medical specialist holds a red heart connected via technology and artificial intelligence (AI)

Image source: Getty Images

The Race Oncology Ltd (ASX: RAC) share price is rising today after the company announced positive findings on its anti-cancer drug trials.

At the time of writing, Race Oncology shares are in the green, up 4.47% trading at $3.27.

Race Oncology is a Sydney-based company working on clinical development and commercialisation of the anti-cancer drug Zantrene.

What did the company announce today?

Race Oncology is investigating if Zantrene can protect the heart from damage by other drugs.

In today’s release, the company said preclinical studies showed that Zantrene was able to “protect heart muscle cells from a new class of anti-cancer drug (Carfilzomib)-induced cell death” while also improving its ability to kill cancer cells.

Race advised it has submitted a patent application “addressing the combination of Zantrene with carfilzomib for the protection of the heart of cancer patients”. If granted, the patent would cover the clinical use of the drug combination until 2041, it said.

The company added that its findings opened up a potential for collaboration with other companies. Carfilzomib is owned by US pharmaceutical giant Amgen, Inc.

Race Oncology advised its next steps included conducting animal studies early next year and performing more preclinical studies on other anti-cancer drugs.

What did management say?

Speaking about the news potentially driving the Race Oncology share price today, CEO Phillip Lynch said:

This additional result further underscores the potential patient utility and commercial applicability for Zantrene.

We will be allocating additional resources to ensure this discovery can be comprehensively addressed.

Race Oncology share price snapshot

The Race Oncology share price has surged this year to date, up 86%. It is also up almost 55% over the past 12 months.

For comparison, the benchmark All Ordinaries Index (ASX: XAO) is up nearly 11% over the last year.

The yearly high for the share price is $4.23, while the yearly low was $1.62.

Based on its current price of $3.27, Race Oncology has a market capitalisation of around $489 million.

Should you invest $1,000 in Race Oncology right now?

Before you consider Race Oncology , you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Race Oncology wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Imugene (ASX:IMU) share price leaps 10% on new Roche deal

Key Points Imugene shares rocket on back of new supply agreement with Roche Clinical trial of PD1-Vaxx will be combined …

Read more »

Lab technician analyses a sample in a laboratory for a clinical trial
Healthcare Shares

Race Oncology (ASX:RAC) share price rises following preclinical discovery

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart …

Read more »

shocked man with hands over his face with a declining graph in background representing falling CleanSpace share price
Healthcare Shares

Why the AnteoTech (ASX:ADO) share price is plummeting 23% on Friday

Key Points AnteoTech shares sink on additional request for information by the TGA The company submitted a performance report last …

Read more »

Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
Healthcare Shares

Why the Imugene (ASX:IMU) share price advanced 5% on market open

Key points Imugene share price soared 5% on the back of European patent approval This is further intellectual protection for …

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Earnings Results

ResMed (ASX:RMD) share price on watch after Q2 update disappoints

Key points ResMed delivered solid revenue and profit growth in the second quarter A major competitor product recall boosted demand …

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Here’s why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

Key points The Rhythm Biosciences share price finished the day up by more than 8% after earlier jumping by 19% …

Read more »

gloved hand holding covid-19 vaccine against backdrop of australian flag
Healthcare Shares

Own CSL (ASX:CSL) shares? Here’s why the company is moving on from COVID research

CSL Limited (ASX: CSL) shares are joining the broader ASX selloff today, down 3.93% to $248.20 per share. The S&P/ASX …

Read more »

Graph showing a fall in share price.
Healthcare Shares

Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

Key points Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday Right now, its share price …

Read more »